190 related articles for article (PubMed ID: 38441582)
1. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL; Maurer MS
JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
[TBL] [Abstract][Full Text] [Related]
2. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
[TBL] [Abstract][Full Text] [Related]
3. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M
Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
Lamb YN
Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
Ruberg FL; Maurer MS; Judge DP; Zeldenrust S; Skinner M; Kim AY; Falk RH; Cheung KN; Patel AR; Pano A; Packman J; Grogan DR
Am Heart J; 2012 Aug; 164(2):222-228.e1. PubMed ID: 22877808
[TBL] [Abstract][Full Text] [Related]
7. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.
Buxbaum JN; Ruberg FL
Genet Med; 2017 Jul; 19(7):733-742. PubMed ID: 28102864
[TBL] [Abstract][Full Text] [Related]
8. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
9. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
10. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M
Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
[TBL] [Abstract][Full Text] [Related]
11. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
12. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
[TBL] [Abstract][Full Text] [Related]
13. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
[TBL] [Abstract][Full Text] [Related]
14. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
15. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
17. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
[TBL] [Abstract][Full Text] [Related]
18. DISCOVERY: prevalence of transthyretin (
Akinboboye O; Shah K; Warner AL; Damy T; Taylor HA; Gollob J; Powell C; Karsten V; Vest J; Maurer MS
Amyloid; 2020 Dec; 27(4):223-230. PubMed ID: 32456532
[TBL] [Abstract][Full Text] [Related]
19. Transthyretin cardiac amyloidoses in older North Americans.
Dharmarajan K; Maurer MS
J Am Geriatr Soc; 2012 Apr; 60(4):765-74. PubMed ID: 22329529
[TBL] [Abstract][Full Text] [Related]
20. Cardiac amyloidosis: a review and report of a new transthyretin (prealbumin) variant.
Hesse A; Altland K; Linke RP; Almeida MR; Saraiva MJ; Steinmetz A; Maisch B
Br Heart J; 1993 Aug; 70(2):111-5. PubMed ID: 8038017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]